文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

托珠单抗在住院Covid-19患者中的疗效

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.
PubMed 文献 · N Engl J Med · 2020-10-21
一句话结论托珠单抗未能预防中度住院Covid-19患者插管或死亡(HR 0.83,95%CI 0.38–1.81),因置信区间宽,不能排除获益或危害。

该随机双盲安慰剂对照试验纳入243例确诊SARS-CoV-2感染、高炎症状态且至少具备发热(体温>38°C)、肺部浸润影或需补氧维持SpO2>92%中两项的住院患者,按2:1随机接受标准治疗加单剂托珠单抗(8 mg/kg)或安慰剂。主要终点插管或死亡的风险比0.83(95%CI 0.38–1.81,P=0.64),疾病恶化HR 1.11(95%CI 0.59–2.10,P=0.73)。14天时托珠单抗组18.0%、安慰剂组14.9%出现疾病恶化;停用补氧中位时间分别为5.0天与4.9天(P=0.69)。结论为托珠单抗对中度住院Covid-19患者预防插管或死亡无效,但置信区间宽,不能排除获益或危害。

要点

  • 纳入243例确诊SARS-CoV-2、高炎症状态且至少两项(体温>38°C、肺部浸润影、需补氧维持SpO2>92%)的住院患者。
  • 托珠单抗组插管或死亡HR 0.83(95%CI 0.38–1.81,P=0.64),与安慰剂无显著差异。
  • 疾病恶化HR 1.11(95%CI 0.59–2.10,P=0.73);14天恶化率托珠单抗组18.0% vs 安慰剂组14.9%。
  • 停用补氧中位时间托珠单抗组5.0天 vs 安慰剂组4.9天(P=0.69);14天仍补氧比例24.6% vs 21.2%。
  • 托珠单抗组严重感染少于安慰剂组;因置信区间宽,不能排除获益或危害。

适用人群与场景

  • 确诊SARS-CoV-2感染、高炎症状态、未接受机械通气且至少具备以下两项的住院患者:发热(体温>38°C)、肺部浸润影、需补氧维持SpO2>92%。

诊断标准与关键阈值

  • 入组条件:确诊SARS-CoV-2感染;高炎症状态;至少两项体征(体温>38°C、肺部浸润影、需补氧维持SpO2>92%);未接受机械通气。

处置流程与药物剂量

  • 标准治疗加单剂托珠单抗8 mg/kg体重(静脉给药,原文未提频次/疗程,按单剂),或标准治疗加安慰剂,随机2:1分配。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 随机双盲安慰剂对照试验,纳入243例住院Covid-19患者(男性141例58%,女性102例42%;中位年龄59.8岁,范围21.7–85.4;45%为Hispanic或Latino),2:1随机接受单剂托珠单抗8 mg/kg或安慰剂。
  • 主要终点插管或死亡:托珠单抗组 vs 安慰剂组 HR 0.83(95%CI 0.38–1.81,P=0.64)。
  • 次要终点疾病恶化:HR 1.11(95%CI 0.59–2.10,P=0.73);14天恶化率托珠单抗组18.0% vs 安慰剂组14.9%。
  • 停用补氧中位时间:托珠单抗组5.0天(95%CI 3.8–7.6) vs 安慰剂组4.9天(95%CI 3.8–7.8),P=0.69;14天仍补氧比例24.6% vs 21.2%。
  • 安全性:托珠单抗组严重感染少于安慰剂组。

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照试验;原文未述证据等级。
  • 局限:原文未述局限性。

对床旁实践的改变

  • 对中度住院Covid-19(未机械通气、符合入组炎症与低氧条件)患者,单剂托珠单抗8 mg/kg未能降低插管或死亡风险(HR 0.83,95%CI 0.38–1.81)。
  • 因置信区间宽,不能排除托珠单抗的获益或危害,临床决策需结合个体情况。
  • 托珠单抗组严重感染少于安慰剂组。

指南或共识出处

  • N Engl J Med:Efficacy of Tocilizumab in Patients Hospitalized with Covid-19(ClinicalTrials.gov NCT04356937)。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: The efficacy of interleukin-6 receptor blockade in hospitalized patients with coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is unclear.

METHODS: We performed a randomized, double-blind, placebo-controlled trial involving patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hyperinflammatory states, and at least two of the following signs: fever (body temperature >38°C), pulmonary infiltrates, or the need for supplemental oxygen in order to maintain an oxygen saturation greater than 92%. Patients were randomly assigned in a 2:1 ratio to receive standard care plus a single dose of either tocilizumab (8 mg per kilogram of body weight) or placebo. The primary outcome was intubation or death, assessed in a time-to-event analysis. The secondary efficacy outcomes were clinical worsening and discontinuation of supplemental oxygen among patients who had been receiving it at baseline, both assessed in time-to-event analyses.

RESULTS: We enrolled 243 patients; 141 (58%) were men, and 102 (42%) were women. The median age was 59.8 years (range, 21.7 to 85.4), and 45% of the patients were Hispanic or Latino. The hazard ratio for intubation or death in the tocilizumab group as compared with the placebo group was 0.83 (95% confidence interval [CI], 0.38 to 1.81; P = 0.64), and the hazard ratio for disease worsening was 1.11 (95% CI, 0.59 to 2.10; P = 0.73). At 14 days, 18.0% of the patients in the tocilizumab group and 14.9% of the patients in the placebo group had had worsening of disease. The median time to discontinuation of supplemental oxygen was 5.0 days (95% CI, 3.8 to 7.6) in the tocilizumab group and 4.9 days (95% CI, 3.8 to 7.8) in the placebo group (P = 0.69). At 14 days, 24.6% of the patients in the tocilizumab group and 21.2% of the patients in the placebo group were still receiving supplemental oxygen. Patients who received tocilizumab had fewer serious infections than patients who received placebo.

CONCLUSIONS: Tocilizumab was not effective for preventing intubation or death in moderately ill hospitalized patients with Covid-19. Some benefit or harm cannot be ruled out, however, because the confidence intervals for efficacy comparisons were wide. (Funded by Genentech; ClinicalTrials.gov number, NCT04356937.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020. PMID: 33085857. doi:10.1056/NEJMoa2028836

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。